GenMark Diagnostics, Inc. engages in the provision of multiplex molecular diagnostic solutions. Its solutions include ePlex System, eSensor, Electrowetting, and XT-8 System. The company was founded by Jon Faiz Kayyem in 1993 and is headquartered in Carlsbad, CA.
Company profile
Ticker
GNMK
Exchange
Website
CEO
Scott Mendel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
272053069
GNMK stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
3 May 21
EFFECT
Notice of effectiveness
28 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Apr 21
Transcripts
GNMK
Earnings call transcript
2020 Q4
26 Feb 21
GNMK
Earnings call transcript
2020 Q3
28 Oct 20
GNMK
Earnings call transcript
2020 Q2
4 Aug 20
GNMK
Earnings call transcript
2020 Q1
4 May 20
GNMK
Earnings call transcript
2019 Q4
2 Mar 20
GNMK
Earnings call transcript
2019 Q3
6 Nov 19
GNMK
Earnings call transcript
2019 Q2
5 Aug 19
GNMK
Earnings call transcript
2019 Q1
30 Apr 19
GNMK
Earnings call transcript
2018 Q4
21 Feb 19
GNMK
Earnings call transcript
2018 Q3
29 Oct 18
Latest ownership filings
SC 13G/A
Consonance Capital Management LP
14 Feb 22
SC 13G/A
WASATCH ADVISORS INC
10 May 21
4
Lisa M. Giles
22 Apr 21
4
Michael Kagnoff
22 Apr 21
4
James Fox
22 Apr 21
4
DARYL FAULKNER
22 Apr 21
4
KEVIN C OBOYLE
22 Apr 21
4
Wade R. Stevenson
22 Apr 21
4
Christine Shaw
22 Apr 21
4
Sarah Hollis Winkler
22 Apr 21
Financial summary
Quarter (USD) | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 42.22 mm | 42.22 mm | 42.22 mm | 42.22 mm | 42.22 mm | 42.22 mm |
Cash burn (monthly) | 5.75 mm | 241.67 k | 695.67 k | 920.92 k | 179.00 k | (no burn) |
Cash used (since last report) | 223.59 mm | 9.40 mm | 27.07 mm | 35.84 mm | 6.97 mm | n/a |
Cash remaining | -181.37 mm | 32.81 mm | 15.15 mm | 6.38 mm | 35.25 mm | n/a |
Runway (months of cash) | -31.6 | 135.8 | 21.8 | 6.9 | 196.9 | n/a |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|